These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31869414)

  • 1. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes.
    Picou F; Vignon C; Debeissat C; Lachot S; Kosmider O; Gallay N; Foucault A; Estienne MH; Ravalet N; Bene MC; Domenech J; Gyan E; Fontenay M; Herault O
    Blood Adv; 2019 Dec; 3(24):4271-4279. PubMed ID: 31869414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
    Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
    Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Dill V; Kauschinger J; Hauch RT; Buschhorn L; Odinius TO; Müller-Thomas C; Mishra R; Kyncl MC; Schmidt B; Prodinger PM; Hempel D; Bellos F; Höllein A; Kern W; Haferlach T; Slotta-Huspenina J; Bassermann F; Peschel C; Götze KS; Waizenegger IC; Höckendorf U; Jost PJ; Jilg S
    Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
    Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
    Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
    Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes.
    Xing T; Lyu ZS; Duan CW; Zhao HY; Tang SQ; Wen Q; Zhang YY; Lv M; Wang Y; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Transl Med; 2022 Mar; 20(1):144. PubMed ID: 35351133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
    Vaxevanis CK; Bauer M; Subbarayan K; Friedrich M; Massa C; Biehl K; Al-Ali HK; Wickenhauser C; Seliger B
    Oncoimmunology; 2023; 12(1):2152998. PubMed ID: 36531688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
    Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
    Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.
    Boehrer S; Adès L; Tajeddine N; Hofmann WK; Kriener S; Bug G; Ottmann OG; Ruthardt M; Galluzzi L; Fouassier C; Tailler M; Olaussen KA; Gardin C; Eclache V; de Botton S; Thepot S; Fenaux P; Kroemer G
    Oncogene; 2009 Jun; 28(22):2205-18. PubMed ID: 19398952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
    Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
    Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
    Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
    PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.